NCT07322757

Brief Summary

Type 2 diabetes is a growing health concern worldwide, influenced by genetic factors, overweight, metabolic syndrome, and insufficient physical activity. Good treatment and glycemic control can reduce or delay diabetes-related complications, which account for a significant and increasing share of healthcare costs in Finland. Much of this cost growth is due to complications resulting from inadequate diabetes care. Secondary prevention programs can therefore provide both health and economic benefits. Lifestyle interventions are one way to improve type 2 diabetes care and reduce complications. This study aims to evaluate the impact of a digital lifestyle intervention combined with optimized care on treatment and outcomes among adults with type 2 diabetes at high risk for complications. The intervention includes access to the BitHabit "Small Actions" application, which supports healthy lifestyle changes, and for participants with a body mass index (BMI) over 30, the Onnikka weight management application. The study will be conducted in North Savo, Finland, using a case-control design. Approximately 120 participants will receive the intervention and 50-100 will serve as controls. All participants will have their care plans reviewed and updated according to the Finnish Current Care Guidelines for Type 2 Diabetes. Control group participants will receive standard care, while the intervention group will receive standard care plus the digital tools. The study also includes the validation of the PAID (Problem Areas in Diabetes) questionnaire for use in Finland and in the Finnish language. The study duration for each participant is 12 months. Data will be collected through physiological measurements, laboratory tests, questionnaires, and app usage logs. Measurements and questionnaires will be conducted at baseline and after 12 months. The analyses will describe the phenomenon, its prevalence, and associations between variables, as well as potential dependencies.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for not_applicable type-2-diabetes

Timeline
19mo left

Started Apr 2025

Typical duration for not_applicable type-2-diabetes

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress41%
Apr 2025Dec 2027

Study Start

First participant enrolled

April 10, 2025

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

December 22, 2025

Completed
16 days until next milestone

First Posted

Study publicly available on registry

January 7, 2026

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2027

Last Updated

January 7, 2026

Status Verified

December 1, 2025

Enrollment Period

2.6 years

First QC Date

December 22, 2025

Last Update Submit

December 22, 2025

Conditions

Keywords

Type 2 diabetesHigh-risk type 2 diabetes patientsDigital lifestyle interventionPROMPAID

Outcome Measures

Primary Outcomes (12)

  • Change from baseline in weight at 12 months

    Change from baseline in weight at 12 months. Weight measurement is taken by study nurse both at baseline and at the end of the study.

    From enrollment to the end of follow-up at 12 months

  • Change from baseline in BMI at 12 months

    Change from baseline in BMI at 12 months. Weight and height measurement are taken by study nurse both at baseline and at the end of the study.

    From enrollment to the end of follow-up at 12 months

  • Change from baseline in waist circumference at 12 months

    Change from baseline in waist circumference at 12 months. Waist circumference is taken by study nurse both at baseline and at the end of the study.

    From enrollment to the end of follow-up at 12 months

  • Change from baseline in Body Roundness Index at 12 months

    Change from baseline in Body Roundness Index at 12 months. Weight, height, waist and hip circumference are taken by study nurse both at baseline and at the end of the study.

    From enrollment to the end of follow-up at 12 months

  • Change from baseline in HbA1c at 12 months

    Change from baseline in HbA1c at 12 months. HbA1c is a laboratory measurement describing glucose levels, taken both at baseline and at the end of the study.

    From enrollment to the end of follow-up at 12 months

  • Change from baseline in serum lipid levels at 12 months

    Change from baseline in serum lipid levels at 12 months. LDL, HDL and triglycerides are laboratory measurements taken both at baseline and at the end of the study.

    From enrollment to the end of follow-up at 12 months

  • Change from baseline in smoking status at 12 months

    Change from baseline in smoking status at 12 months. Smoking status is surveyed both at baseline and at the end of the study.

    From enrollment to the end of follow-up at 12 months

  • Change from baseline in physical activity at 12 months

    Change from baseline in physical activity at 12 months. Physical activity is surveyed both at baseline and at the end of the study.

    From enrollment to the end of follow-up at 12 months

  • Change from baseline in dietary habits at 12 months

    Change from baseline in dietary habits at 12 months. Dietary habits are surveyed both at baseline and at the end of the study.

    From enrollment to the end of follow-up at 12 months

  • Change from baseline in blood pressure at 12 months

    Change from baseline in blood pressure at 12 months. Blood pressure measurement is taken by study nurse via Riva Rocci method both at baseline and at the end of the study.

    From enrollment to the end of follow-up at 12 months

  • Self-reported changes from baseline in qualty of life measured by EQ-5D-5L at 12 months

    EQ-5D-5L is a standard health questionnaire assessing quality of life across five dimensios: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. EQ-5D-5L questionnaire is filled electronically at baseline and at the end of the study.

    From enrollment to the end of follow-up at 12 months

  • Change from baseline in Problem Areas in Diabetes (PAID) scale at 12 months

    PAID scale identifies emotional distress in diabetes, covering issues like worrying complications, goal setting, food, treatment, and social support, common problems including fear, anger, feeling overwhelmed and guilt.

    From enrollment to the end of follow-up at 12 months

Study Arms (2)

Digital intervention arm

EXPERIMENTAL

Digital interventions: BitHabit application and optionally Onnikka application

Other: BitHabit digital application for behavioral lifestyle changesOther: Onnikka weight management digital application

Control group

NO INTERVENTION

Control group receives same enhancement in treatment plan, but no digital interventions

Interventions

BitHabit digital application for behavioral lifestyle changes

Digital intervention arm

Onnikka weight management digital application

Digital intervention arm

Eligibility Criteria

Age35 Years - 74 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Type 2 diabetes diagnosed
  • At least one of the following:
  • diagnosed coronary artery disease,
  • diagnosed periferal artery disease,
  • diagnosed heart failure,
  • diagnosed diabetic renal disease (GFR \<60 OR uACR ≥ 3 for at least three months),
  • diagnosed diabetic retinopathy,
  • previous stroke,
  • diagnosed atrial fibrillation or atrial flutter,
  • age ≥ 55 years and at least two of the following conditions:
  • smoker
  • uses antihypertensive medication or systolic blood pressure \>140 mmHg or diastolic blood pressure \> 80 mmHg,
  • uses lipid lowering medication or LDL-cholesterol \> 2.6 or
  • BMI \> 25

You may not qualify if:

  • eGFR \< 30
  • uACR \> 200
  • BMI \> 50
  • heart ejection fraction EF \< 30
  • active cancer or less than five years from cancer treatment at enrollment
  • blindness in both eyes
  • severe psychotic depression
  • inability to utilize digital applications

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Wellbeing services county of North Savo, Nursing and Physician Services

Kuopio, Northern Savonia, Finland

RECRUITING

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Officials

  • Sonja Soininen, MD, PhD

    Wellbeing Services County of North Savo, Kuopio, Finland

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Physician in Chief, Teaching clinic Osmo

Study Record Dates

First Submitted

December 22, 2025

First Posted

January 7, 2026

Study Start

April 10, 2025

Primary Completion (Estimated)

December 1, 2027

Study Completion (Estimated)

December 1, 2027

Last Updated

January 7, 2026

Record last verified: 2025-12

Data Sharing

IPD Sharing
Will not share

Study permission does not allow sharing individual participant data.

Locations